Clinical efficacy of hyperbaric oxygen combined with idebenone in the treatment of Parkinson's disease and mechanism of action
Objective To explore the clinical efficacy of hyperbaric oxygen(HBO)combined with idebenone in the treatment of Parkinson's disease and its effect on the expressions of serum human chitinase protein 40(YKL-40)and osteopontin(OPN).Methods A prospective study was conducted on 96 elderly patients with Parkinson's disease in the Huaihe Hospital of Henan University and Neurlogy Department of Kaifeng Central Hospital from November 2019 to November 2022.The patients were divided into control group and observation group,by the random number table method,with 48 cases in each group.The control group patients were treated with idebenone,while the observation group patients were additionally treated with HBO.The unified Parkinson's disease rating scale(UPDRS)and Montreal cognitive assessment scale(MoCA)were adopted to evaluate patients'cognitive function and clinical treatment outcomes.The enzyme linked immunosorbent assay(ELISA)was applied to detect serum OPN and YKL-40 expression levels in two groups before and after treatment.Results The total effective rate of treatment of the observation group(89.58％)was significantly higher than that of the control group(72.91％),with a statistically significant difference(x2=4.376,P=0.036).After treatment,the UPDRS Ⅰ,UPDRS Ⅱ,and UPDRS Ⅲ scores of the observation group were significantly lower than those of the control group,and the MoCA score was significantly higher than that of the control group(P＜0.01).Compared with those before treatment,the serum expression levels of OPN and YKL-40 in the two groups decreased significantly after treatment(P＜0.01),and those of the observation group was significantly lower than the control group after treatment(P＜0.05).Conclusion The combination of HBO and idebenone has good clinical efficacy in the treatment of Parkinson's disease in elderly patients,which can significantly improve their cognitive functions,effectively reduce serum YKL-40 and OPN expression levels,thus having good clinical application value.
NETL
NSTL
万方数据
